Skip to main content
Terug
Watch Compare

Jin Medical International Ltd.

Datakwaliteit: 100%
ZJYL
Nasdaq Manufacturing Measuring & Analyzing Instruments
€ 2,31
▲ € 0,20 (9,48%)
Marktkapitalisatie: 17,53 M
Prijs
€ 2,24
Marktkapitalisatie
17,53 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Earnings declined -67,59% over the past year
ROE of 4,40% is below average
Negative free cash flow of -3,73 M
P/E of 14,72 — trading at a low valuation
Capital intensive — 32,05% of revenue goes to capex
ROIC of 1,32% — low return on invested capital

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-11,98%
Earnings (1Y)-67,59%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
4,40%
Boven sectorgemiddelde (-53,34%)
ROIC1,32%
Net Margin5,76%
Op. Margin2,94%

Veiligheid

Debt / Equity
0,56
Boven sectorgemiddelde (0,31)
Current Ratio2,11
Interest CoverageN/A

Waardering

PE (TTM)
14,72
Boven sectorgemiddelde (-1,47)
P/B Ratio0,63
EV/EBITDA39,06
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E 14,7 -1,5
P/B 0,6 1,6
ROE % 4,4 -53,3
Net Margin % 5,8 -41,5
Rev Growth 5Y % — 1,8
D/E 0,6 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 € 0,01
N/A – N/A
 21,13 M —

All Fundamental Metrics
Growth
Revenue Growth (1Y) -11,98% Revenue Growth (3Y) 2,16%
Earnings Growth (1Y) -67,59% Earnings Growth (3Y) -35,67%
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 20,69 M Net Income (TTM) 1,19 M
ROE 4,40% ROA 2,66%
Gross Margin 29,22% Operating Margin 2,94%
Net Margin 5,76% Free Cash Flow (TTM) -3,73 M
ROIC 1,32% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,56 Current Ratio 2,11
Interest Coverage N/A Asset Turnover 0,46
Working Capital 23,04 M Tangible Book Value 26,82 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 14,72 Forward P/E N/A
P/B Ratio 0,63 P/S Ratio 0,85
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 39,06 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -21,25%
Market Cap 17,53 M Enterprise Value 33,26 M
Per Share
EPS (Diluted TTM) 0,01 Revenue / Share 2,64
FCF / Share -0,48 OCF / Share 0,37
EPS CAGR (1Y) -50,00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 32,05% FCF Conversion -312,79%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 20,69 M 23,50 M 19,82 M
Net Income 1,19 M 3,68 M 2,88 M
EPS (Diluted) 0,01 0,02 0,02
Gross Profit 6,04 M 9,50 M 6,78 M
Operating Income 608.182,0 3,64 M 2,87 M
EBITDA — — —
R&D Expenses 1,56 M 1,50 M 1,54 M
SG&A Expenses — — —
D&A 243.403,0 237.823,0 225.902,0
Interest Expense — — 182.682,0
Income Tax 214.572,0 763.879,0 343.707,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 53,37 M 45,80 M 32,90 M
Total Liabilities 23,80 M 17,25 M 8,92 M
Shareholders' Equity 29,64 M 28,82 M 23,98 M
Total Debt 18,84 M 11,32 M —
Cash & Equivalents — — —
Current Assets 44,14 M 42,82 M 31,12 M
Current Liabilities 23,80 M 17,15 M 8,92 M